{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:57:05Z","timestamp":1776578225093,"version":"3.51.2"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jcyt.2020.02.001","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:17:04Z","timestamp":1586909824000},"page":"369-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2326-7133","authenticated-orcid":false,"given":"Rajeswaran","family":"Mani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0301-4582","authenticated-orcid":false,"given":"Girish","family":"Rajgolikar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1403-5103","authenticated-orcid":false,"given":"Jessica","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevan","family":"Zapolnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronni","family":"Wasmuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9797-2687","authenticated-orcid":false,"given":"Xiaokui","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-5392","authenticated-orcid":false,"given":"Dean A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natarajan","family":"Muthusamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2020.02.001_bib0001","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3389\/fimmu.2017.00631","article-title":"The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments","volume":"8","author":"Veluchamy","year":"2017","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jcyt.2020.02.001_bib0002","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2012.87","article-title":"Natural killer cell immune escape in acute myeloid leukemia","volume":"26","author":"Lion","year":"2012","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jcyt.2020.02.001_bib0003","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1158\/1078-0432.CCR-15-3168","article-title":"Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future","volume":"22","author":"Muntasell","year":"2016","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"23","key":"10.1016\/j.jcyt.2020.02.001_bib0004","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2015-11-680546","article-title":"Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts","volume":"127","author":"Vasu","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jcyt.2020.02.001_bib0005","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2009-06-227934","article-title":"CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells","volume":"115","author":"Baessler","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2020.02.001_bib0006","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/0008-5472.CAN-08-2650","article-title":"Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans","volume":"69","author":"Baessler","year":"2009","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.jcyt.2020.02.001_bib0007","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood-2018-03-838474","article-title":"Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function","volume":"132","author":"Scoville","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2020.02.001_bib0008","doi-asserted-by":"crossref","first-page":"11154","DOI":"10.1038\/ncomms11154","article-title":"Repression of GSK3 restores NK cell cytotoxicity in AML patients","volume":"7","author":"Parameswaran","year":"2016","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.jcyt.2020.02.001_bib0009","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrd4506","article-title":"Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens","volume":"14","author":"Childs","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"6013","key":"10.1016\/j.jcyt.2020.02.001_bib0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jcyt.2020.02.001_bib0011","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jcyt.2020.02.001_bib0012","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jcyt.2020.02.001_bib0013","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1182\/blood-2016-07-730564","article-title":"Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translation","volume":"128","author":"Mancusi","year":"2016","journal-title":"Blood"},{"issue":"5562","key":"10.1016\/j.jcyt.2020.02.001_bib0014","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2020.02.001_bib0015","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood cancer journal"},{"issue":"4","key":"10.1016\/j.jcyt.2020.02.001_bib0016","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","article-title":"The past and future of CD33 as therapeutic target in acute myeloid leukemia","volume":"28","author":"Laszlo","year":"2014","journal-title":"Blood reviews"},{"issue":"26","key":"10.1016\/j.jcyt.2020.02.001_bib0017","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"issue":"7661","key":"10.1016\/j.jcyt.2020.02.001_bib0018","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jcyt.2020.02.001_bib0019","doi-asserted-by":"crossref","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jcyt.2020.02.001_bib0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/cei.12034","article-title":"Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation","volume":"172","author":"Wang","year":"2013","journal-title":"Clin Exp Immunol"},{"issue":"16","key":"10.1016\/j.jcyt.2020.02.001_bib0021","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jcyt.2020.02.001_bib0022","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3324\/haematol.2018.188193","article-title":"The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia\/myelodysplastic syndrome patients and healthy donors","volume":"103","author":"Mani","year":"2018","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jcyt.2020.02.001_bib0023","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2017.21","article-title":"Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858","volume":"31","author":"Eksioglu","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jcyt.2020.02.001_bib0024","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.18632\/oncotarget.23880","article-title":"Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia","volume":"9","author":"Gopalakrishnan","year":"2018","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.jcyt.2020.02.001_bib0025","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1182\/blood-2012-06-437558","article-title":"A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission","volume":"120","author":"Vey","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcyt.2020.02.001_bib0026","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nri3174","article-title":"Targeting natural killer cells and natural killer T cells in cancer","volume":"12","author":"Vivier","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2020.02.001_bib0027","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3389\/fimmu.2013.00481","article-title":"Combination immune therapies to enhance anti-tumor responses by NK cells","volume":"4","author":"Mentlik James","year":"2013","journal-title":"Front Immunol"},{"issue":"23","key":"10.1016\/j.jcyt.2020.02.001_bib0028","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2020.02.001_bib0029","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/1078-0432.CCR-15-1419","article-title":"The IL-15-Based ALT-803 Complex Enhances FcgammaRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas","volume":"22","author":"Rosario","year":"2016","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"13","key":"10.1016\/j.jcyt.2020.02.001_bib0030","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv"},{"issue":"357","key":"10.1016\/j.jcyt.2020.02.001_bib0031","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Science translational medicine"},{"key":"10.1016\/j.jcyt.2020.02.001_bib0032","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4939-9728-2_12","article-title":"An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells","volume":"2048","author":"Zhu","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"9","key":"10.1016\/j.jcyt.2020.02.001_bib0033","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ni.3518","article-title":"Targeting natural killer cells in cancer immunotherapy","volume":"17","author":"Guillerey","year":"2016","journal-title":"Nat Immunol"},{"issue":"13","key":"10.1016\/j.jcyt.2020.02.001_bib0034","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","article-title":"Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9","volume":"119","author":"Gleason","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2020.02.001_bib0035","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jcyt.2020.02.001_bib0036","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/bloodadvances.2017015230","article-title":"Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy","volume":"2","author":"Mastaglio","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2020.02.001_bib0037","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fimmu.2017.00432","article-title":"Distinct Effects of Dexamethasone on Human Natural Killer Cell Responses Dependent on Cytokines","volume":"8","author":"Morgan","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2020.02.001_bib0038","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ajh.22201","article-title":"Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1\/2 study of the acute leukemia French association","volume":"87","author":"Farhat","year":"2012","journal-title":"American journal of hematology"},{"issue":"4","key":"10.1016\/j.jcyt.2020.02.001_bib0039","article-title":"How close are we to CAR T-cell therapy for AML?, Best practice & research","volume":"32","author":"Gill","year":"2019","journal-title":"Clinical haematology"},{"issue":"6","key":"10.1016\/j.jcyt.2020.02.001_bib0040","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"issue":"6","key":"10.1016\/j.jcyt.2020.02.001_bib0041","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324920300372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324920300372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:41:00Z","timestamp":1761442860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324920300372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1465324920300372"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2020.02.001","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2020.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of International Society for Cell and Gene Therapy.","name":"copyright","label":"Copyright"}]}}